Compare ON Holding AG (ONON) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ON Holding AG vs Regeneron Pharmaceuticals Inc — how do they compare? ON Holding AG trades at $34.16 (market cap $11.10B), while Regeneron Pharmaceuticals Inc trades at $737.72 (market cap $76.40B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 6.9× ON Holding AG's market cap, and Regeneron Pharmaceuticals Inc pays a 0.51% dividend while ON Holding AG pays none. Which is the better fit depends on your goals — on Pluang, investors hold ON Holding AG for 22 Days and Regeneron Pharmaceuticals Inc for 107 Days on average.
| ONON | REGN | |
|---|---|---|
Market Cap | $11.10B | $76.40B |
Volume | 8,202,649 | 626,381 |
Sector | Consumer Cyclical | Health |
52-Week High | $50.63 | $852.03 |
52-Week Low | $26.76 | $557.73 |
Typical Hold Time | 22 Days | 107 Days |
Enterprise Value | $10.26B | $71.12B |
Dividend Yield | — | 0.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ONON trades at $33.22, up 0.27% with a bullish technical outlook supported by moving averages. The company demonstrates strong fundamentals with Q2 2026 EPS beating expectations at $0.44 vs. $0.42, maintaining a three-quarter beat streak. Recent investor day announcements include a $1 billion buyback program and ambitious 2029 targets of CHF 5.6B in sales with 22% EBITDA margins, driving positive sentiment.
The stock offers growth potential with 74% analyst buy ratings and a $42.26 consensus target, representing 27% upside. Key risks include elevated valuation multiples (P/E 23.41, P/S 5.52) and competitive pressure in footwear. Strong cash flow generation ($359.5M operating cash flow in 2025) supports the buyback and expansion plans.
Regeneron Pharmaceuticals (REGN) trades at $739.57, up 0.12% on the day, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company maintains robust profitability with a net income margin of 27.86%. A major $8 billion expansion of the immunology alliance with Sanofi, announced October 1, 2026, provides significant future revenue potential and strategic momentum.
The outlook is positive, supported by strong earnings, a lucrative partnership, and a consensus analyst price target of $846. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. The stock presents a compelling opportunity for growth investors, though volatility may persist near-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About ON Holding AG
ON Holding AG is a Swiss sports company primarily known for its high-performance running shoes, apparel, and accessories under the 'On' brand. The company emphasizes a blend of high-end design, proprietary cloud technology (like CloudTec cushioning), and sustainability in its products. On has rapidly gained market share globally, appealing to both competitive athletes and general consumers in the performance and lifestyle footwear segments.
Read more on ONON →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
